Mesoblast Ltd: Form 20-F for the period ended Jun 30, 2023
Filed with the SEC on Aug 31, 2023 and accepted by EDGAR at Aug 30, 2023, 21:06 ET.
Sections
Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2023-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 12 months2022-07-01 to 2023-06-30 | $7.5m | ifrs-full:Revenue |
| Income tax | 12 months2022-07-01 to 2023-06-30 | −$212.0k | ifrs-full:IncomeTaxExpenseContinuingOperations |
| Net income | 12 months2022-07-01 to 2023-06-30 | −$81.9m | ifrs-full:ProfitLossAttributableToOwnersOfParent |
| Diluted EPS | 12 months2022-07-01 to 2023-06-30 | −$0.11 | ifrs-full:DilutedEarningsLossPerShare |
| Basic EPS | 12 months2022-07-01 to 2023-06-30 | −$0.11 | ifrs-full:BasicEarningsLossPerShare |
| Operating cash flow | 12 months2022-07-01 to 2023-06-30 | −$63.3m | ifrs-full:CashFlowsFromUsedInOperatingActivities |
| Cash and equivalents | At period end2023-06-30 | $71.3m | ifrs-full:CashAndCashEquivalents |
| Current assets | At period end2023-06-30 | $81.7m | ifrs-full:CurrentAssets |
| Total assets | At period end2023-06-30 | $669.4m | ifrs-full:Assets |
| Current liabilities | At period end2023-06-30 | $42.0m | ifrs-full:CurrentLiabilities |
| Total liabilities | At period end2023-06-30 | $167.6m | ifrs-full:Liabilities |
| Shareholders' equity | At period end2023-06-30 | $501.8m | ifrs-full:Equity |
| Shares outstanding | At period end2023-06-30 | 814,204,825 shares | dei:EntityCommonStockSharesOutstanding |
Source: SEC EDGAR, the filing index for accession 0001345099-23-000059. Last ingested by Listed: Oct 29, 2026, 06:58 ET. Listed shows no prices and gives no investment advice.